The combination of computational capabilities with advanced technologies of gene expression at the single cell level in space allowed PVRIG to be seen at the foci of T cell activation in the tumor environment Preliminary findings continue to support the rationale of PVRIG inhibition to overcome resistance to immunotherapy
Compugen (NASDAQ: CGEN, Tel Aviv: Kempeg), a cancer immunotherapy company in clinical development stages that develops computational drug discovery, announced that it will present data on the study of the cellular environment of cancerous tumors (TME) using advanced technologies for tracking gene expression at the single cell level in space. The data was presented yesterday at the Keystone Symposium: Cancer Immunotherapy: Decoding the Cancer Immunity Interactome, which takes place in Canada, between March 21-24, 2022.
Dr. Anat Cohen-Daig, president and CEO of Compugen, said, "Compugen's computational platform is the cornerstone of our drug discovery and development capabilities. The biology of the TME is complex, and a deep understanding of it is required to develop new cancer immunotherapies. At the Keystone conference, we will report on our successful use of high-resolution spatial mapping of gene expression at a The Single Cell To decipher this complexity, we leveraged our long-standing expertise in computational biology Immuno-oncology using state-of-the-art technology to provide an unprecedented view of the composition and spatial distribution of individual cells in the TME. Preliminary findings add to and support the presence of the DNAM-1 axis, including PVRIG, an immune regulatory protein discovered by Compugen, in foci. of T cell activation, including in tertiary lymphoid structures This finding is important because it confirms previous findings and adds to and supports the rationale of blocking PVRIG to overcome resistance to immunotherapy in inflamed and less inflamed tumors. Our ability to study tumors at the single cell level expands our understanding of the complex interactions in the TME and opens the door to new therapeutic approaches."
Compugen's cloud-based computational platform combines the company's gene and protein expression data, public databases, clinical data and machine learning to discover new immuno-oncology therapeutic targets, biomarkers and mechanisms of action. The hypotheses that are based on the computational processes are quickly tested and verified in the company's biological laboratories. The verified information is often added back to the computational discovery loop and provides another layer of data that is used to improve the computational models. The close integration between computational methods and experimental data is one of Compugen's strengths and has proven its importance in the company's discoveries in the field of immuno-oncology, in the clinical development programs and in the advancement of the company's drug pipeline.
More of the topic in Hayadan:
